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ABSTRACT
Osteopenia is a frequent, often persistent, complication of anorexia
nervosa (AN) in adolescent girls and occurs during a critical time in
bone development. Little is known about bone metabolism in this
patient population. Therefore, we measured bone density (BMD) and
body composition by dual energy x-ray absorptiometry, nutritional
status, bone turnover, calcium, and hormonal status in 19 adolescent
girls with AN (mean 6 SEM, 16.0 6 0.4 yr) and 19 bone age-matched
controls. The mean duration of AN was 19 6 5 months. Spinal (L1–L4)
osteopenia was common in AN. Lumbar anterioposterior BMD was
more than 1 SD below the mean in 42% of patients, and lateral spine
BMD was more than 1 SD below in 63% of patients compared with
controls. Lean body mass significantly predicted lumbar bone mineral
content (r 5 0.75; P , 0.0001) in controls only. In AN, duration of
illness was the most significant predictor of spinal BMD (lumbar: r 5
20.44; P 5 0.06; lateral: r 5 20.59; P 5 0.008). AN adolescents with
mature BA (15 yr and greater) were hypogonadal [estradiol, 16.2 6
1.9 vs. 23.3 6 1.6 pg/mL (P 5 0.01); free testosterone, 0.70 6 0.17 vs.
1.36 6 0.14 pg/mL (P 5 0.01)] although dehydroepiandrosterone sul-
fate and urinary free cortisol levels did not differ. Leptin levels were
reduced in AN (2.9 6 2.1 vs. 16.5 6 1.8 ng/mL; P , 0.0001). Insulin-
like growth factor I (IGF-I) was reduced in AN to 50% of control levels
(219 6 41 vs. 511 6 35 ng/mL; P , 0.0001) and correlated with all
measures of nutritional status, particularly leptin (r 5 0.80; P ,
0.0001). Surrogate markers of bone formation, serum osteocalcin (OC)
and bone-specific alkaline phosphatase (BSAP), were significantly
(P 5 0.02) reduced in AN vs. controls (OC, 39.1 6 6.4 vs. 59.2 6 5.2
ng/mL; BSAP, 27.9 6 4.0 vs. 40.6 6 3.4 U/L). The majority of the
variation in bone formation in AN was due to IGF-I levels (OC: r2 5
0.72; P 5 0.002; BSAP: r2 5 0.53; P 5 0.01) in stepwise regression
analyses. Bone resorption was comparable in patients and controls.
These data demonstrate that bone formation is reduced and uncou-
pled to bone resorption in mature adolescents with AN in association
with low bone density. Lean body mass was a significant predictor of
BMD in controls, but not AN patients. The major correlate of bone
formation in AN was the nutritionally dependent bone trophic factor,
IGF-I. Reduced IGF-I during the critical period of bone mineral ac-
cumulation may be an important factor in the development of os-
teopenia in adolescents with AN. (J Clin Endocrinol Metab 84: 4489–
4496, 1999)
ANOREXIA NERVOSA (AN) is an increasingly commondisorder in adolescent girls, with a prevalence of 0.2–
1.0% in Western societies (1, 2). Osteopenia is a frequent and
often persistent complication of AN in this young population
(3–6), leading to clinical fractures and increased fracture risk
throughout life (7, 8). A severe degree of decreased bone
mass has been reported even in young adolescents with a
brief duration of illness (3). Adolescence represents a critical
time in bone metabolism, as most bone mineral is accumu-
lated during the teenage years, and deficits incurred during
this time may be permanent. Therefore, an understanding of
the factors that impact bone density during this time period
is of particular importance.
Bone density and bone metabolism change dramatically
during adolescence, and the onset of AN during this critical
time may interfere with achievement of peak bone mass. In
addition, significant changes in body weight and composi-
tion, pubertal development, and pubertal hormones, such as
estradiol and insulin-like growth factor I (IGF-I), occur in AN
and may impact bone metabolism. The effect of AN on bone
turnover in adolescent girls is poorly understood. Limited data
are available (9, 10), and prior studies in adolescents with AN
have been limited by the small numbers of subjects and the lack
of information about specific biochemical markers of bone turn-
over, including simultaneous measurements of formation and
resorption. Moreover, previous studies have included subjects
of a broad age range from early adolescence to young adult-
hood. Finally, pubertal and skeletal maturation have not been
measured in assessments of bone density, even though bone
density correlates more with pubertal stage and bone age (BA)
than chronological age (CA) (11, 12).
The purpose of this study was to further characterize bone
metabolism and potential mechanisms of osteopenia in ad-
olescents with AN in a cohort of adolescent females in whom
bone density, biochemical indices of bone turnover, nutri-
tional status, and pubertal hormones were determined com-
pared with those in BA-matched controls. Our data demon-
strate significant osteopenia in adolescent girls with AN.
Bone formation indices are significantly reduced in associ-
ation with IGF-I and other nutritionally dependent factors in
this population of patients, suggesting a profound effect of
this disease on osteoblast function.
Subjects and Methods
Subjects
We studied 38 Caucasian adolescent girls, 19 with AN, and 19 healthy
adolescents. The AN patients were 12.8–18.5 yr of age. All met DSM IV
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criteria for AN, with duration since diagnosis ranging from 2–72 months.
Only 1 patient had concomitant bulimia. All patients had either primary
(n 5 2) or secondary (n 5 12; duration, 6–48 months) amenorrhea or
were premenarchal (n 5 5). Two patients with secondary amenorrhea
had taken estrogen previously (for 6–18 months), but not within 3
months of the study. Patients receiving hormonal or other medications
known to affect bone metabolism were excluded. A history of traumatic
bone fracture was reported during childhood or adolescence in 32% of
AN patients, but none occurred within 6 months of the study. Subjects
were recruited through mass mailings to primary health care providers
and through collaboration with eating disorder programs in the greater
Boston area.
A control group of 19 healthy Caucasian female adolescents, aged
13.1–17.8 yr, was recruited by advertisement in primary care providers’
offices and community newspapers. All had a body mass index (BMI;
kilograms per meter squared) between the 25th-90th percentile for age
based on published standard charts (13). One control subject, 13.1 yr old,
was premenarchal. All postmenarchal adolescents had regular men-
strual periods. None of the controls had a history of an eating disorder.
Control subjects with a medical condition or receiving hormonal or other
medications known to affect bone metabolism were excluded. A history
of traumatic bone fracture during childhood or adolescence was re-
ported in 42% of control subjects, but none occurred within 6 months of
the study.
The study protocol was approved by the Massachusetts General
Hospital subcommittee on human subjects, and informed consent was
obtained from all subjects and their parents.
Experimental protocol
All subjects were evaluated during an out-patient visit at the General
Clinical Research Center at Massachusetts General Hospital after a
screening visit to determine eligibility and give instruction on collection
of urine samples and completion of 4-day food records. A medical and
menstrual history and physical examination were performed by a single
investigator. All control subjects were studied during the early follicular
phase of the menstrual cycle to control for the effects of cycle stage on
biochemical and hormonal measurements. All AN and control subjects
had their BA determined by x-ray of the left hand and wrist by a single
investigator using the methods of Greulich and Pyle (14).
Subjects’ height was measured using a single stadiometer (average of
triplicate measurements), and weight was measured in a hospital gown
on an electronic scale. BMI was calculated, and BMI percentile was
determined from published charts (13).
Subjects collected a 24-h and a 2-h second morning urine sample at
home. All had fasting blood samples drawn at the same time of day
(afternoon). Urine and serum samples were obtained for biochemical
and hormonal measurements as outlined below. Bone density and body
composition were assessed in all subjects.
Classification of subjects by bone age
For the analysis of biochemical parameters that are dependent on
pubertal stage, such as gonadal steroids and markers of bone formation
and resorption, we subdivided groups by maturity. Previous studies
reported significant changes in bone turnover markers between girls in
Tanner stages 2–3 and 4–5 (15, 16). Tanner breast staging is difficult to
assess in females with AN who are hypoestrogenemic and have breast
atrophy, whereas BA provides more objective information on past and
current maturation. We therefore subdivided subjects into immature
(BA, ,15 yr) and mature (BA, $15 yr) groups. We used the cut-off BA
of 15 yr because this BA is mature, in that all epiphyses are near fusion,
and 99% of final adult height has been attained according to the stan-
dards of Greulich and Pyle (14). Biochemical data are available for the
mature group only, because there were insufficient numbers of imma-
ture subjects based on initial power calculations.
Biochemical assessment
Serum ionized calcium, phosphorus, TSH, dehydroepiandrosterone
sulfate, and 24-h urinary free cortisol (UFC), calcium, and creatinine
were measured through the hospital laboratory using previously de-
scribed methods (17).
Serum estradiol (E2) was measured by ultrasensitive RIA (Diagnostics
Systems Laboratories, Inc., Webster, TX). The detection limit of the E2
assay is 2.2 pg/mL, and the coefficient of variation is 6.5–8.9%. Total and
free testosterone (T) were measured by RIA (Coat-A-Count, Diagnostic
Products, Los Angeles, CA). Total T had a detection limit of 20 ng/dL
and an intraassay coefficient of variation of 10–15%, and free T had a
detection limit of 0.57 pg/mL and an intraassay coefficient of variation
of 3.2–4.3%. Serum IGF-I was measured by acid-alcohol extraction using
a RIA kit (Nichols Institute Diagnostics, San Juan Capistrano, CA), with
a detection limit of 0.06 ng/mL and an intraassay coefficient of variation
2.4–3.0%. Serum leptin was measured by RIA (Linco Research, Inc., St.
Louis, MO) with a sensitivity of 0.5 ng/mL and an intraassay coefficient
of variation of 3.4–8.3%. Serum 25-hydroxyvitamin D was measured by
RIA (DiaSorin, Inc., Stillwater, MN), with a detection limit of 3 ng/mL
and a coefficient of variation of 10–13%. Serum intact PTH was mea-
sured by a two-site immunoradiometric assay (Nichols Institute Diag-
nostics, San Juan Capistrano, CA) with a detection limit of 1 pg/mL and
an intraassay coefficient of variation of 1.8–3.4%. Serum osteocalcin (OC)
was measured using an immunoradiometric assay (Nichols Institute
Diagnostics) with a sensitivity of 0.5 ng/mL and an intraassay coefficient
of variation of 3.2–5.2%. Bone-specific alkaline phosphatase (BSAP) was
measured by immunoassay (Metra Biosystems, Mountain View, CA)
with a sensitivity of 0.7 U/L and a coefficient of variation of 3.9–5.8%.
Carboxyl-terminal propeptide of type 1 procollagen was measured by
RIA with an intraassay coefficient of variation of 2.1–3.2% (INCSTAR
Corp., Stillwater, MN). Urinary deoxypyridinoline (DPD) and
N-telopeptide (NTX) were measured in a 2-h second morning urine
sample normalized for creatinine excretion. DPD was measured by
competitive enzyme-linked immunoassay (Metra Biosystems) with a
minimum detection limit of 1.1 nmol/L and an intraassay coefficient of
variation of 4.3–8.4%. NTX was measured by enzyme-linked immu-
nosorbent assay (Ostex International, Inc., Seattle, WA) with a detection
limit of 20 nmol BCE and an intraassay coefficient of variation of 5–19%.
All samples were run in duplicate using a single kit.
Bone density and body composition
Total body and lumbar spine (L1–L4) bone densitites were measured
using a QDR-4500 (Hologic, Inc., Waltham, MA). The sd for bone density
measurement is 0.01 g/cm2 and does not vary with bone density.
Whole body dual energy x-ray absorptiometry (DEXA) was per-
formed using a Hologic, Inc. QDR-4500 densitometer to determine fat
and lean body mass, which has been validated in children and young
adults (18, 19).
Nutritional assessment
Nutritional intake data, including calorie, protein, fat, carbohydrate,
and micronutrient content, were obtained through computer analysis
(version 2, Nutrition Data Systems, Minneapolis, MN) of 4-day food
records and history of dietary intake over the month before the study
visit. Resting metabolic energy expenditure was performed using a
metabolic cart (20). Typical exercise and activity of subjects over the past
year were determined using a validated questionnaire (21).
Statistical analysis
Clinical, bone density, body composition, and biochemical data were
analyzed with Student’s t test and compared by linear regression anal-
ysis. Stepwise regression analyses were performed to determine the
relationship of anthropometric, body composition, and hormonal data
to bone density and bone turnover. Significance was set at P , 0.05 for
all comparisons. Results are the mean 6 sem unless otherwise indicated.
Results
Clinical and anthropometric data
Clinical and anthropometric data for patients and controls
are summarized in Table 1. Patients were matched for BA
(15.7 vs. 15.5 yr) with control subjects. CA was not signifi-
cantly different between the AN and controls groups. How-
ever, BA compared with CA (BA/CA) was significantly
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lower in the AN subjects compared with controls (AN, 0.98 6
0.01; control, 1.03 6 0.01; P 5 0.01). Duration of AN was 19 6
5 months, and duration of amenorrhea was 24 6 4 months.
Height was not significantly different between the groups.
AN patients were of significantly lower weight and BMI. In
the AN group, fat mass measured by DEXA was less than
50% that in controls (AN, 7.7 6 0.8; control, 19.6 6 0.8 kg; P ,
0.0001), and percent body fat was substantially reduced (AN,
17.7 6 1.3%; control, 33.5 6 1.3%; P , 0.0001). Lean body
mass was also significantly lower in AN subjects (AN, 33.1 6
1.0; control, 37.1 6 1.0 kg; P 5 0.01) even when controlled for
height and body weight.
Historical assessment of activity level over the past year
demonstrated that AN subjects were significantly more
physically active than controls, with approximately twice as
many hours of physical activity per week (AN, 17.0 6 2.2;
control, 9.4 6 2.2 h/week; P 5 0.02). Resting metabolic en-
ergy expenditure was significantly lower in AN subjects
(AN, 1314 6 60; control, 1587 6 60 KCal/day). No subjects
regularly smoked cigarettes or consumed alcohol.
Nutritional data
Analysis of intake by 4-day food record and diet history
produced similar results; therefore, only the data for food
records are provided in Table 2. Patients were in various
stages of illness, and there was considerable variability in
intake reported by the two groups. The major difference in
dietary intake between the groups was reduced fat intake
(AN, 41 6 7; control, 65 6 7 g; P 5 0.03) and percentage of
calories from fat (AN, 20 6 2%; control, 28 6 2%; P 5 0.005)
in AN subjects. Fifty-three percent of AN patients and 67%
of controls had a calcium intake less than the Recommended
Daily Allowance of calcium despite calcium supplementa-
tion in approximately 23%. In 53% of AN patients and 78%
of controls, vitamin D intake was less than the Recom-
mended Daily Allowance despite vitamin D supplementa-
tion in approximately 30% of subjects.
Bone density data
Bone density data are summarized in Table 3. Lumbar
spine (L1–L4) BMD was significantly lower in the AN sub-
jects (AN, 0.87 6 0.02; control, 0.97 6 0.02 g/cm2; P 5 0.004).
Lumbar bone mineral content (BMC) was also reduced in AN
(AN, 45 6 2; control, 51 6 2 g; P 5 0.04), with lumbar area
not different between the groups. In 42% of AN subjects
lumbar BMD was more than 1 sd below the mean for the
healthy, height- and BA-matched controls. Sixteen percent of
AN subjects had a lumbar BMD more than 2 sd below the
normal mean. Comparison of the subjects’ lumbar spine
BMD to the DEXA manufacturer normative data also dem-
TABLE 2. Daily nutrient intake
Anorexia nervosa (n 5 17) Control (n 5 18) P value
Calories (KCal) 1730 6 162 [668–2913] 2042 6 162 [1395–4093] NS
Fat (g) 41 6 7 [7–88] 65 6 7 [26–162] 0.03
% Cal from fat 20 6 2 [16–33] 28 6 2 [16–41] 0.005
Protein (g) 72 6 6 [31–128] 70 6 6 [40–122] NS
Carbohydrate (g) 282 6 23 [113–458] 303 6 23 [213–588] NS
Calcium (mg) 1297 6 131 [580–2333] 1238 6 128 [589–2708] NS
% ,RDA 53% 67%
Vitamin D (IU) 423 6 62 [112–1212] 302 6 60 [80–714] NS
% ,RDA 53% 78%
Phosphorus (mg) 1396 6 131 [570–2476] 1383 6 127 [741–2551] NS
Magnesium (mg) 368 6 34 [149–606] 310 6 33 [173–586] NS
Dietary supplementation
Calcium 24% 22% NS
Vitamin D 35% 28% NS
Values are expressed as the mean 6 SEM. Ranges are in brackets. The P value is for comparison between anorexia nervosa and control subjects
by Student’s t test.
TABLE 1. Clinical and anthropometric data
Anorexia nervosa (n 5 19) Control (n 5 19) P value
Chronological age (yr) 16.0 6 0.4 [12.8–18.5] 15.1 6 0.4 [13.1–17.8] NS
Bone age (yr) 15.7 6 0.3 [13–18] 15.5 6 0.3 [13–18] NS
Bone age/chronological age 0.98 6 0.01 1.03 6 0.01 0.01
Ht (cm) 162.3 6 1.4 164.7 6 1.4 NS
Wt (kg) 43.4 6 1.5 58.6 6 1.5 ,0.0001
BMI (kg/m2) 16.5 6 0.4 21.8 6 0.4 ,0.0001
Duration of illness (months) 19 6 5 [2–72]
Amenorrhea
No. premenarchal 5 1
No. primary 2 0
No. secondary 12 0
Duration (months) 24 6 4 [6–48]
Activity (h/week) 17.0 6 2.2 9.4 6 2.2 0.02
MEE (kCal/day) 1314 6 60 1587 6 60 0.003
All values are expressed as the mean 6 SEM. Ranges are in brackets. The P value is for comparison between anorexia nervosa and control
subjects by Student’s t test. MEE, Resting metabolic energy expediture.
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onstrated that the AN group had significantly lower lumbar
BMD (AN z-score, 21 6 0.3; controls z-score, 0.2 6 0.3; P 5
0.002), with a z-score below 21 in 50%, and below 22 in 21%
of AN patients. The reduction in lateral spine BMD was even
more severe in AN (AN, 0.68 6 0.02; control, 0.81 6 0.02
g/cm2; P , 0.0001), with BMD more than 1 sd below the
normal mean in 63% of patients and more than 2 sd below
the normal mean in 26% of patients. Total body BMC (TBMC)
was reduced in AN (AN, 1700 6 53; control, 1889 6 53 g; P 5
0.02) and total body BMD (TBMD) was lower in AN, but not
significantly. Differences in spinal BMD and TBMC re-
mained significant when controlled for height. Similar dif-
ferences in bone mineral apparent density were demon-
strated (AN, 0.122 6 0.003; control, 0.132 6 0.003 g/cm3; P 5
0.02), using the formula of Katzman et al. (22).
In the control group, lean body mass was the single most
significant predictor of lumbar BMC (r 5 0.75; P , 0.0001)
and lateral spine (r 5 0.55; P 5 0.003) and total (r 5 0.54; P 5
0.004) BMD. These correlations remained significant when
controlled for height and weight, but weight rather than lean
body mass was a more significant determinant of lumbar
BMD when controlled for height. The relationships between
body weight, composition, BMC, and BMD were not present
in AN. In AN, duration of illness was the most important
determinant of lumbar BMD (r 5 20.44; P 5 0.06) and BMC
(r 5 20.42; P 5 0.07) and lateral spine BMD (r 5 20.59; P 5
0.008), but not TBMD or TBMC. In addition, duration of
amenorrhea (r 5 20.58; P , 0.05) was predictive of lateral
spine BMD.
Biochemical data
TSH and serum ionized calcium and phosphorus were
normal in all subjects. Calcium excretion in a 24-h urine
collection was normal in all subjects, with the exception of
one AN subject who was ingesting 2100 mg calcium daily
with a dietary supplement. The median 24-h urinary calcium
was 144 mg in both groups (range in AN, 71–450 mg; in
control, 39–217 mg). UFC in a 24-h collection was not sig-
nificantly different between groups (AN, 59 6 7; control, 51 6
7 mg), although 33% of AN subjects (6 of 18) had modest
elevations in UFC.
Serum PTH levels were normal in all subjects and were not
different between the groups (Table 4). Serum 25-hydroxyvi-
tamin D levels were lower in the control group, but normal
in all subjects, and correlated with dietary vitamin D intake
(r 5 0.41; P 5 0.03).
Serum E2 levels were significantly reduced, even in com-
parison with controls sampled in the early follicular phase
(Table 4). There was a trend toward lower total T levels in
AN, and free T levels were markedly reduced (AN, 0.70 6
0.17; control, 1.36 6 0.14 pg/mL; P 5 0.006), with levels
below the lower limit of detection of the assay in 82% of AN
subjects.
Serum IGF-I levels were reduced significantly in AN, to
less than 50% of those in the control subjects (AN, 219 6 41;
control, 511 6 35 ng/mL; P , 0.0001). Leptin was also mark-
edly reduced in AN (AN, 2.9 6 2.1; control, 16.5 6 1.8 ng/mL;
P , 0.0001), to less than 20% of control levels. In all subjects,
IGF-I levels correlated highly with nutritional status, includ-
ing BMI (r 5 0.73; P , 0.0001), percent body fat (r 5 0.61; P 5
0.0008), lean body mass (r 5 0.49; P 5 0.005), and leptin (r 5
0.80; P , 0.0001). In contrast, there was no relationship be-
tween IGF-I and gonadal steroid concentrations. In stepwise
regression analysis including all anthropometric and bio-
chemical measurements, leptin accounted for 65% of the
variation in IGF-I levels (r2 5 0.65; P , 0.00001). Leptin was
highly dependent on fat mass (r 5 0.78; P , 0.0001).
Bone turnover marker results are summarized in Table 5
and Fig. 1. OC and BSAP were significantly lower in AN
patients than in normal subjects. DPD and NTX were not
significantly different between the groups. However, there
was a trend toward lower NTX levels in the AN group. There
was a strong correlation between IGF-I and OC in AN sub-
jects (r 5 0.71; P 5 0.01; Fig. 2), whereas in the control group
a similar trend was found, but the correlation did not reach
statistical significance (r 5 0.46; P 5 0.07). In stepwise re-
TABLE 4. Serum hormone concentrations
Anorexia
nervosa
(n 5 11)
Control
(n 5 15) P value
25-Hydroxyvitamin D (ng/mL) 37 6 3 29 6 3 0.05
PTH (pg/mL) 24.8 6 3.6 32.8 6 3.1 NS
Estradiol (pg/mL) 16.2 6 1.9 23.3 6 1.6 0.01
Total testosterone (ng/dL) 23.6 6 3.4 32.5 6 2.9 0.06
Free testosterone (pg/mL) 0.70 6 0.17 1.36 6 0.14 0.01
DHEAS (mg/dL) 223 6 31 212 6 26 NS
IGF-I (ng/mL) 219 6 41 511 6 35 ,0.0001
Leptin (ng/mL) 2.9 6 2.1 16.5 6 1.8 ,0.0001
Serum hormone data in mature (bone age of 15 yr or greater)
subjects. Values are expressed as the mean 6 SEM. The P value if for
comparison between anorexia nervosa and control subjects by Stu-
dent’s t test.
TABLE 3. Bone density and body composition data
Anorexia nervosa
(n 5 19)
Control
(n 5 19) P value
P value for ht-adjusted
BMD
LBMD, L1–4 (g/cm2) 0.87 6 0.02 0.97 6 0.02 0.004 0.01
LBMC, L1–4 (g) 45 6 2 51 6 2 0.04 0.03
Lateral spine BMD (g/cm2) 0.68 6 0.02 0.81 6 0.02 ,0.0001 0.0002
Total BMD (g/cm2) 1.01 6 0.02 1.04 6 0.02 NS NS
TBMC (g) 1700 6 53 1889 6 53 0.02 0.02
Fat (kg) 7.7 6 0.8 19.6 6 0.8 ,0.0001 NA
% Body fat 17.7 6 1.3 33.5 6 1.3 ,0.0001 NA
Lean (kg) 33.1 6 1.0 37.1 6 1.0 0.01 NA
All values are expressed as the mean 6 SEM. The P value is for comparison between anorexia nervosa and control subjects by Student’s t
test. NA, Not applicable.
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gression analysis, IGF-I accounted for 72% (r2 5 0.72; P 5
0.002), and IGF-I and free T together accounted for 95% (r2
5 0.95; P 5 0.0006), of the variation in OC levels in AN. There
was a similar strong relationship between IGF-I and BSAP in
the AN group (r 5 0.73; P 5 0.01; Fig. 2) and the control group
(r 5 0.59; P 5 0.02). In stepwise regression analysis, IGF-I was
the only significant predictor of BSAP, accounting for 53%
(r2 5 0.53; P 5 0.01) of the variation in BSAP in AN and 35%
(r2 5 0.35; P 5 0.01) in controls.
Adult height
Subjects in the mature group, who had a minimum BA of
15 yr, were determined to be at adult height. When adult
height was compared to midparental target height, height
was significantly reduced in the AN group, on the average
3.0 cm below midparental height (AN, 23.0 6 1.0; control,
0.2 6 0.9 cm; P 5 0.02). Furthermore, only one subject in the
AN group exceeded her midparental target height, com-
pared with eight (53%) control subjects.
Discussion
In this study, we have characterized bone density and bone
metabolism in adolescent girls with AN compared with those
in BA-matched controls. Bone formation indices and bone
density are significantly reduced in adolescents with AN.
Moreover, low bone formation in this population was
strongly associated with markedly diminished IGF-I, a nu-
tritionally dependent endogenous bone trophic factor. In
addition, we have shown that in these osteopenic girls the
decrease in bone formation is uncoupled from bone
resorption.
Our data demonstrate that spinal osteopenia is common in
adolescent girls with AN compared with a group of BA- and
CA-matched healthy adolescents. In the patient group, 42%
of AN subjects had a lumbar spine BMD more than 1 sd, and
16% had a lumbar spinal BMD more than 2 sd, below the
mean of the BA- and height-matched controls despite an
average duration of illness of only 1.5 yr. The results of lateral
spine BMD, which may be more representative of trabecular
bone (23), demonstrated even more severe osteopenia, with
BMD more than 1 sd below the mean in 63% and more than
2 sd in 26% of AN patients compared with controls. Fur-
thermore, we obtained similar results for height-adjusted
and bone mineral apparent density calculations, suggesting
that the low BMD was not an artifact of size.
Previous studies of bone metabolism in adolescents with
AN have been limited by the small numbers of subjects,
inclusion of a broad age range, and lack of information about
specific biochemical markers of bone turnover, including
measures of both formation and resorption. To assess further
the mechanisms of reduced BMD in AN we characterized
bone metabolism in adolescents with AN compared with that
in a CA- and BA-matched group of healthy adolescents.
Studies of adult women with AN demonstrate a severe im-
balance in bone turnover, with a decrease in markers of bone
formation combined with an increase in markers of bone
resorption (24). However, data obtained from women with
AN cannot be extrapolated to adolescent patients who are in
an active period of bone growth and mineral accretion as well
as remodeling. Abrams et al. demonstrated that adolescents
with AN have decreased calcium absorption and increased
urinary calcium excretion; however, bone markers were not
measured (9). Saggese et al. reported low levels of carboxyl-
terminal propeptide of type 1 procollagen, a bone formation
marker, in six adolescent AN patients ranging from 11–21 yr
of age, but did not investigate other markers of formation or
markers of resorption in these patients (10).
Matching patients with controls based on stage of matu-
ration is critical in the evaluation of bone metabolism, as both
bone formation and resorption markers change dramatically
with the transition from early (Tanner stage 2–3) to late
(Tanner stage 4–5) puberty (15, 16). Furthermore, levels of
bone formation and resorption remain above adult levels
even in mature (Tanner stage 5) adolescents (15). We chose
to classify maturation in adolescents based on BA because
assessment of Tanner stage in adolescents with AN who are
hypoestrogenemic is difficult and likely to be inaccurate. In
our study, all healthy controls who had a BA of 15 yr or
greater had Tanner stage 4–5 development and therefore
were classified as mature. In contrast, 35% of AN patients
with a mature BA had what appeared clinically to be Tanner
stage 3 breast tissue. Therefore, Tanner staging as a measure
of pubertal maturation in AN can be inaccurate, whereas BA
provides a more objective classification.
Bone formation indexes, OC and BSAP, were significantly
reduced in mature adolescents with AN in contrast to those
in healthy mature adolescents. In contrast, markers of bone
resorption, DPD and NTX, were not significantly different,
although there was a trend toward lower NTX in AN sub-
jects. Therefore, in healthy adolescents, high levels of bone
formation and resorption were seen. In contrast, patients
with AN had low bone formation with normal resorption.
Although biochemical markers are indirect measures of bone
growth and remodeling, resorption indexes are generally
thought to reflect degradation of existing bone, whereas for-
mation indices in adolescents are thought to reflect skeletal
growth and mineralization. We speculate that in a low met-
abolic state such as AN, remodeling continues, and bone
formation associated with growth and bone mineral accu-
mulation is reduced. We were unable to measure bone me-
tabolism in the immature adolescents due to insufficient
numbers of subjects and therefore could not determine
whether the balance of bone formation and resorption is also
altered in immature patients with AN. Further studies in
younger patients will provide insight as to whether reduced
TABLE 5. Bone turnover markers
Anorexia
nervosa
(n 5 11)
Control
(n 5 15) P value
OC (ng/mL) 39.1 6 6.4 59.2 6 5.2 0.02
BSAP (U/L) 27.9 6 4.0 40.6 6 3.4 0.02
PICP (ng/mL) 139 6 12 154 6 10 NS
DPD (nmol/mmol creatinine) 13.4 6 1.4 15.1 6 1.2 NS
NTX (nmol BCE/mmol
creatinine)
138 6 25 200 6 21 NS
Bone turnover markers in mature (bone age of 15 yr or more)
subjects. Values are expressed as the mean 6 SEM. The P value if for
comparison between anorexia nervosa and control subjects by Stu-
dent’s t test.
BONE TURNOVER IN GIRLS WITH ANOREXIA 4493
bone formation in AN is dependent on the stage of
maturation.
The primary correlate of bone formation in AN was the
level of IGF-I, which was markedly reduced in AN subjects,
in contrast to the high levels expected and found in normal
adolescents. IGF-I functions as a bone trophic hormone,
which positively affects bone growth and bone turnover by
stimulating osteoblasts, collagen synthesis, and longitudinal
bone growth (25, 26). Low levels of serum IGF-I are present
in undernutrition and correlate with low BMI in AN (24, 27,
28). We found a high correlation between all indexes of
nutritional status, including body composition variables and
particularly leptin, with IGF-I levels, indicting that under-
nutrition is a major cause of reduced IGF-I levels in adoles-
cents with AN. These data indicate that IGF-I deficiency due
to undernutrition could significantly contribute to low bone
formation in adolescents with AN.
In healthy adolescents, E2 is thought to contribute signif-
icantly to bone mineral acquisition, either by acting directly
on bone or by stimulating other mediators of bone growth
(12, 29). In this study, in contrast to other studies (15, 29), we
determined bone turnover during the early follicular phase
of the menstrual cycle when E2 is at low levels to control for
effects of cycle stage on bone metabolism. Significant effects
of the menstrual cycle on OC and BSAP have been described
in women, showing that osteoblast activity is higher during
the luteal phase (30). We have described a reduction in bone
formation between AN and controls at a point in the men-
strual cycle when levels of bone formation in controls are
relatively reduced. Therefore, the degree of reduction in in-
dexes of bone formation might be even greater after the
follicular phase.
Hypoestrogenemia has been proposed as a contributing
factor to the low bone density in AN, because primary or
secondary amenorrhea is a nearly universal feature. In ad-
olescents, lower lumbar bone density is seen in amenorrheic
teens compared with those with normal menses, but is not
significant when patients are controlled for body weight (31,
32). In fact, gains in bone density may precede the return of
menses in patients recovering from AN (4). Estrogen treat-
ment in young women with AN has not caused improvement
in bone density in a randomized, prospective trial (33), but
has not been investigated in adolescent AN patients. In our
study, duration of illness was the most predictive of AP and
lateral spine BMD. Our data suggest that nutritional status
may be an independent determinant of bone density.
This study demonstrates that in addition to estrogen de-
ficiency, adolescents with AN have markedly diminished
levels of total and free T, with free T undetectable in the
majority of patients. In contrast, dehydroepiandrosterone
sulfate levels were not different between the groups, sug-
gesting a relatively greater deficiency in gonadal than ad-
FIG. 1. Comparison of bone turnover markers in mature subjects with AN (n 5 11) and controls (n 5 15). Results are the mean 6 SEM. OC
and BSAP, *, P 5 0.02; deoxypyridinoline (DPD), P 5 NS. The P value is for comparison of AN subjects vs. BA-matched controls.
FIG. 2. Correlation between IGF-I and bone formation markers in
mature subjects (BA, 15 yr or greater) with AN (n 5 11).
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renal androgen production. These data are in agreement with
recent data demonstrating that in pubertal adolescents the
ovaries are the major source of serum T, in contrast to pre-
puberty when the adrenals are the primary source (34). Pos-
itive correlations between total and free T and bone forma-
tion (OC) have been demonstrated in adult women during
the normal menstrual cycle, including the follicular phase
(35), although this has not been reported in adolescents. In
our group of AN adolescents, OC was determined in part by
free T in stepwise regression analysis.
Nutritional factors, particularly body weight and lean
body mass, are critical determinants of bone mass in ado-
lescent girls (36, 37). Our data demonstrate markedly re-
duced fat mass, percent body fat, and lean body mass in AN
adolescents even when controlled for height and weight. In
healthy normal weight and obese children (5–18 yr), lean
body mass had the highest correlation with total bone min-
eral content (36). Bachrach et al. reported that BMI correlated
highly with bone density when adolescents with AN and
controls were analyzed together, but in the AN group alone
there was no correlation (3). In our study, lean body mass was
the only body composition variable that contributed signif-
icantly to total and regional (total and lumbar BMC and
lateral spine BMD) bone density in healthy adolescent girls.
However, determinants of bone mass in AN may differ from
those in healthy girls. Similar to the relationship between
BMI and BMD described by Bachrach et al. (3), our data show
that when the AN and control groups were analyzed to-
gether, lean body mass significantly correlated with lumbar
BMD (r 5 0.49; P 5 0.005); however, in the AN group alone
this relationship was not present.
An important finding in our study is that dietary calcium
and vitamin D deficiency are prevalent in our study popu-
lation of both AN patients and normal adolescent girls. As
has been reported in other studies of adolescent girls (38, 39),
a majority of girls were deficient in dietary calcium intake
during a time when calcium requirements are maximal (40),
even though 23% of all girls studied were receiving dietary
supplements. Calcium intake has been shown to correlate
with bone density in healthy children and adolescents (11,
41), and calcium supplementation has been shown to in-
crease bone density in studies of healthy adolescents, al-
though the effect may be dependent on pubertal stage (38,
39). Most of our adolescent subjects also had deficient vita-
min D intake. Although all of our study subjects had normal
serum 25-hydroxyvitamin D and PTH levels, the AN group
had higher 25-hydroxyvitamin D levels that correlated with
vitamin D intake. Our data indicate that most adolescent girls
may not get sufficient amounts of these important nutrients
with food intake alone; therefore, routine supplementation in
many adolescent girls may be warranted. No correlation
between calcium intake and BMD in adolescents with AN
was demonstrated in this study, and it is unknown whether
BMD could be improved by calcium and vitamin D supple-
mentation in adolescents with AN.
Other factors that may affect BMD, including UFC and
exercise, were investigated, but did not impact BMD in this
study. We did not find a relationship between UFC and
lumbar BMD as has been described in adult women with AN
(6), although 33% of the AN patients had elevations in UFC.
Physical activity, particularly weight-bearing exercise, is
known to have positive effects on bone density in children
and adolescents (11, 41), although heavy exercise during
adolescence may lead to delayed puberty and low bone den-
sity (42). In this study, physical activity was significantly
higher in the AN group, probably contributing to their low
weight and amenorrhea. However, there was no relationship
between amount of physical activity and BMD in either
group. Some patients may have relatively normal BMD de-
spite low weight due to a previous environmental exposure
(i.e. prepubertal exercise) or inherited factors, such as vitamin
D receptor or COLA1A polymorphisms, which may be pro-
tective (43–46) but were not systematically evaluated in this
study.
Adolescents with AN have been reported to have de-
creased linear growth rate and adult height (47, 48); however,
adult height in this population of patients in comparison
with genetic target height has not been reported. We found
that mature AN adolescents were, on the average, 3.0 cm
below their genetic target height compared with healthy
adolescents who, on the average, reached their genetic target
height. The reason for reduced growth in AN could not be
evaluated in this cross-sectional cohort and will require lon-
gitudinal study, but reduced circulating IGF-I resulting in
low bone formation is one potential mechanism.
This is the first study to describe low bone formation in
BA- and CA-matched adolescents with AN, in whom bone
formation is highly correlated with serum levels of IGF-I.
Low bone formation may result in reduced peak bone ac-
cumulation and eventual severe osteopenia, as seen in adult
women with AN. Low IGF-I due to undernutrition in addi-
tion to gonadal steroid deficiency during the critical adoles-
cent period may be an important factor contributing to the
pathogenesis of osteopenia in AN.
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